- €25.90bn
- €27.06bn
- €6.15bn
- 97
- 13
- 66
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.18 | ||
| PEG Ratio (f) | 0.39 | ||
| EPS Growth (f) | 77.81% | ||
| Dividend Yield (f) | 1.05% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.58 | ||
| Price to Tang. Book | 53.41 | ||
| Price to Free Cashflow | 28.16 | ||
| Price to Sales | 4.21 | ||
| EV to EBITDA | 13.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.58% | ||
| Return on Equity | 11.21% | ||
| Operating Margin | 21.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 5,347 | 5,777 | 5,517 | 5,252 | 6,152 | 6,771.6 | 7,620.19 | 4.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +0.88 | +25.84 | -54.22 | -45.38 | +131.2 | +127.14 | +26.81 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Directors
- Jean-Christophe Tellier CMG (62)
- Pierre Gurdjian NVC (60)
- Sandrine Dufour CFO (54)
- Jean-Luc Fleurial CHO (56)
- Dhavalkumar Patel EVP (60)
- Bill Silbey EVP (61)
- Emmanuel Caeymaex EVP (52)
- Iris Loewfriedrich EVP (60)
- Kirsten Lund-jurgensen EVP (61)
- Charl Van Zyl EVP (53)
- Antje Witte VPR
- Xavier Michel SEC
- Charles-Antoine Janssen NED (50)
- Cyril Janssen NED (49)
- Cedric Van Rijckevorsel NED (50)
- Jan Berger IND (63)
- Kay Davies NID (69)
- Albrecht De Graeve NID (65)
- Viviane Monges NID (58)
- Ulf Wiinberg NID (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 11th, 2011
- Public Since
- January 2nd, 1987
- No. of Employees
- 9,378
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Euronext - Brussels- Shares in Issue
- 190,042,407
- Address
- Allee de la Recherche, 60, ANDERLECHT, 1070
- Web
- https://www.ucb.com
- Phone
- +32 25599999
- Contact
- Antje Witte
- Auditors
- Mazars Reviseurs d Entreprises SCRL
Upcoming Events for UCB
Dividend For UCB.BR - 1.3900 EUR
Dividend For UCBJY.PK - 0.7911 USD
UCB SA Annual Shareholders Meeting
Half Year 2025 Ucb SA Earnings Release
Similar to UCB
Biosenic SA
Euronext - Brussels
Fagron NV
Euronext - Brussels
Hyloris Pharmaceuticals SA
Euronext - Brussels
Financiere de Tubize SA
Euronext - Brussels
FAQ
What is the UCB SA share price?
As of Today at 23:50 UTC, shares in UCB SA are trading at €136.30. This share price information is delayed by 15 minutes.
How has the UCB SA share price performed this year?
Shares in UCB SA last closed at €136.30 and the price had moved by +13.68% over the past 365 days. In terms of relative price strength the UCB SA share price has outperformed the FTSE Global All Cap Index by +11.68% over the past year.
What are the analyst and broker recommendations for UCB SA?
The overall consensus recommendation for UCB SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the UCB SA dividend yield?
The UCB SA dividend yield is 0.71% based on the trailing twelve month period.
Does UCB SA pay a dividend?
Last year, UCB SA paid a total dividend of €0.97, and it currently has a trailing dividend yield of 0.71%.Looking ahead, shares in UCB SA are due to go ex-dividend on 2025-04-25 and the next dividend pay date is 2025-04-29.
When does UCB SA next pay dividends?
UCB SA are due to go ex-dividend on 2025-04-25 and the next dividend pay date is 2025-04-29. The historic dividend yield on UCB SA shares is currently 0.71%.
How do I buy UCB SA shares?
To buy shares in UCB SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of UCB SA?
As of the previous close price of €136.30, shares in UCB SA had a market capitalisation of €25.90bn.
Where are UCB SA shares listed?
Here are the trading details for UCB SA:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: UCB
What kind of share is UCB SA?
Based on an overall assessment of its quality, value and momentum UCB SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a UCB SA share price forecast for 2025?
The analyst consensus target price for shares in UCB SA is €207.40. That is 52.16% above the last closing price of €136.30.
Analysts covering UCB SA currently have a consensus Earnings Per Share (EPS) forecast of €7.35 for the next financial year.
Find out moreWhat is the trend in the UCB SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like UCB SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.37%.
As of the last closing price of €136.30, shares in UCB SA were trading -20.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the UCB SA PE Ratio?
The UCB SA PE ratio based on its reported earnings over the past 12 months is 17.18. The shares last closed at €136.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of UCB SA?
UCB SA's management team is headed by:
- Jean-Christophe Tellier - CMG
- Pierre Gurdjian - NVC
- Sandrine Dufour - CFO
- Jean-Luc Fleurial - CHO
- Dhavalkumar Patel - EVP
- Bill Silbey - EVP
- Emmanuel Caeymaex - EVP
- Iris Loewfriedrich - EVP
- Kirsten Lund-jurgensen - EVP
- Charl Van Zyl - EVP
- Antje Witte - VPR
- Xavier Michel - SEC
- Charles-Antoine Janssen - NED
- Cyril Janssen - NED
- Cedric Van Rijckevorsel - NED
- Jan Berger - IND
- Kay Davies - NID
- Albrecht De Graeve - NID
- Viviane Monges - NID
- Ulf Wiinberg - NID